<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362559">
  <stage>Registered</stage>
  <submitdate>1/06/2012</submitdate>
  <approvaldate>4/06/2012</approvaldate>
  <actrnumber>ACTRN12612000598886</actrnumber>
  <trial_identification>
    <studytitle>The effect of the drug resiniferatoxin on the bladder as a treatment for cases of incontinence previously unresponsive to treatment.</studytitle>
    <scientifictitle>25-90 year old females with urodynamically proven refractory idiopathic detrusor activity given resiniferatoxin  to assess the benefits of resiniferatoxin treatment on frequency volume chart, quality of life, leakage pad tests.</scientifictitle>
    <utrn>U1111-1131-3439</utrn>
    <trialacronym>RTX for Refractory IDO</trialacronym>
    <secondaryid>Therapeutic Goods Administration CTN: 2004/236</secondaryid>
    <secondaryid>Therapeutic Goods Administration: Protocol Number: RTX01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Refractory idiopathic detrusor overactivity</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>10 mL of 500nM (50nM) resiniferatoxin stock was diluted with 90mL of sterile saline and stored in dark,sterile conditions at 20 degrees C (Final concentration: 0.00314mg/100mL).  This was instilled in the bladder for 30 minutes and drained via a urinary catheter. This intervention was administered to each participant on one occasion only</interventions>
    <comparator>uncontrolled</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Frequency volume chart (Voids per day/night)</outcome>
      <timepoint>Prior to commencement, 1 month and 3 months after resiniferatoxin treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>International Consultation on Incontinence Questionnaire (ICIQ)</outcome>
      <timepoint>Prior to commencement, 1 month and 3 months after resiniferatoxin treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Urogenital Distress Inventory (UDI)</outcome>
      <timepoint>Prior to commencement, 1 month and 3 months after treatment with resiniferatoxin</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>24 hour Pad testing (grams of leakage per 24 hours)</outcome>
      <timepoint>Prior to commencement, 1 month and 3 months after resiniferatoxin treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incontinence Impact Questionnaire (IIQ)</outcome>
      <timepoint>Prior to commencement, 1 month and 3 months after resiniferatoxin treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Urodynamically proven idiopathic detrusor overactivity refractory to at least two anticholinergic treatments for 12 months</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pure stress incontinence, current bacterial cystitis, neurological disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>30/05/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Pelvic Floor Unit Research Fund (St George Hospital)</primarysponsorname>
    <primarysponsoraddress>St George Hospital
Department of Urogynaecology
Gray St
Kogarah NSW 2217</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Pelvic Floor Unit Research Fund (St George Hospital)</fundingname>
      <fundingaddress>St George Hospital
Department of Urogynaecology
Gray St
Kogarah NSW 2217</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This project involves administering a solution into the bladder to treat incontinence, which ahs already been used in eight countries overseas. Urge incontinence (detrusor overactivity (DO)) is treated with anticholinergic drugs which are generally palliative, not curative. Bladder instillation of vanilloids i.e. capsaicin and resiniferatoxin (RTX) for DO has shown symptomatic improvement for up to 3 months. We wish to offer this therapy for urge incontinent women who have not responded to two anticholinergic drugs. RTX will be instilled into the bladder via a urinary catheter. Women will be assessed at 1 and 3 months by routine measures. This novel project will study which types of DO respond best to the treatment</summary>
    <trialwebsite />
    <publication>Moore KH, Allen W, Leek H, Bushati T, Woodman J, Burcher E. Response to resiniferatoxin disappointing in idiopathic detrusor overactivity. Proc. 3rd Annual Meeting on Advances in Urogenital Research. 2006; 8-9</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>SESIAHS Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Management Office
St George Hospital
3rd Floor James laws House
Gray Street, Kogarah
NSW 2217</ethicaddress>
      <ethicapprovaldate>20/04/2004</ethicapprovaldate>
      <hrec>04/43 Moore</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Kate H Moore</name>
      <address>St George Hospital
Pitney Clinical Sciences Building
Short St, Kogarah
NSW 2217</address>
      <phone>+61 2 9113 2054</phone>
      <fax />
      <email>k.moore@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Kate H Moore</name>
      <address>St George Hospital
Pitney Clinical Sciences Building
Short St, Kogarah
NSW 2217</address>
      <phone>+61 2 9113 2054</phone>
      <fax />
      <email>k.moore@unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Kate H Moore</name>
      <address>St George Hospital
Pitney Clinical Sciences Building
Short St, Kogarah
NSW 2217</address>
      <phone>+61 2 9113 2054</phone>
      <fax />
      <email>k.moore@unsw.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>